Barclays lowered the firm’s price target on Elevance Health (ELV) to $358 from $434 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong Revenue Growth in Q2 2025
- Elevance Health Earnings Call: Growth Amid Challenges
- Bernstein Calls UnitedHealth Stock (UNH) a Top Pick Ahead of Q2 Earnings
- Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks
- Elevance Health downgraded to Market Perform from Outperform at Leerink